171 related articles for article (PubMed ID: 34951366)
41. Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce beta-amyloid related to Alzheimer's disease.
Hook V; Hook G; Kindy M
Biol Chem; 2010 Aug; 391(8):861-72. PubMed ID: 20536395
[TBL] [Abstract][Full Text] [Related]
42. BACE1 Mediates HIV-Associated and Excitotoxic Neuronal Damage Through an APP-Dependent Mechanism.
Stern AL; Ghura S; Gannon PJ; Akay-Espinoza C; Phan JM; Yee AC; Vassar R; Gelman BB; Kolson DL; Jordan-Sciutto KL
J Neurosci; 2018 May; 38(18):4288-4300. PubMed ID: 29632166
[TBL] [Abstract][Full Text] [Related]
43. Nuclear factor-κB regulates βAPP and β- and γ-secretases differently at physiological and supraphysiological Aβ concentrations.
Chami L; Buggia-Prévot V; Duplan E; Del Prete D; Chami M; Peyron JF; Checler F
J Biol Chem; 2012 Jul; 287(29):24573-84. PubMed ID: 22654105
[TBL] [Abstract][Full Text] [Related]
44. Clec4g (LSECtin) interacts with BACE1 and suppresses Aβ generation.
Kizuka Y; Kitazume S; Sato K; Taniguchi N
FEBS Lett; 2015 Jun; 589(13):1418-22. PubMed ID: 25957769
[TBL] [Abstract][Full Text] [Related]
45. MiR-340 Reduces the Accumulation of Amyloid-β Through Targeting BACE1 (β-site Amyloid Precursor Protein Cleaving Enzyme 1) in Alzheimer's Disease.
Tan X; Luo Y; Pi D; Xia L; Li Z; Tu Q
Curr Neurovasc Res; 2020; 17(1):86-92. PubMed ID: 31957613
[TBL] [Abstract][Full Text] [Related]
46. Camelid heavy chain only antibody fragment domain against β-site of amyloid precursor protein cleaving enzyme 1 inhibits β-secretase activity in vitro and in vivo.
Dorresteijn B; Rotman M; Faber D; Schravesande R; Suidgeest E; van der Weerd L; van der Maarel SM; Verrips CT; El Khattabi M
FEBS J; 2015 Sep; 282(18):3618-31. PubMed ID: 26147692
[TBL] [Abstract][Full Text] [Related]
47. Increased expression of reticulon 3 in neurons leads to reduced axonal transport of β site amyloid precursor protein-cleaving enzyme 1.
Deng M; He W; Tan Y; Han H; Hu X; Xia K; Zhang Z; Yan R
J Biol Chem; 2013 Oct; 288(42):30236-30245. PubMed ID: 24005676
[TBL] [Abstract][Full Text] [Related]
48. BACE1: the beta-secretase enzyme in Alzheimer's disease.
Vassar R
J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
[TBL] [Abstract][Full Text] [Related]
49. Regulation of Synaptic Amyloid-β Generation through BACE1 Retrograde Transport in a Mouse Model of Alzheimer's Disease.
Ye X; Feng T; Tammineni P; Chang Q; Jeong YY; Margolis DJ; Cai H; Kusnecov A; Cai Q
J Neurosci; 2017 Mar; 37(10):2639-2655. PubMed ID: 28159908
[TBL] [Abstract][Full Text] [Related]
50. Transcriptional and translational regulation of BACE1 expression--implications for Alzheimer's disease.
Rossner S; Sastre M; Bourne K; Lichtenthaler SF
Prog Neurobiol; 2006 Jun; 79(2):95-111. PubMed ID: 16904810
[TBL] [Abstract][Full Text] [Related]
51. The circular RNA ciRS-7 promotes APP and BACE1 degradation in an NF-κB-dependent manner.
Shi Z; Chen T; Yao Q; Zheng L; Zhang Z; Wang J; Hu Z; Cui H; Han Y; Han X; Zhang K; Hong W
FEBS J; 2017 Apr; 284(7):1096-1109. PubMed ID: 28296235
[TBL] [Abstract][Full Text] [Related]
52. Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis.
Velliquette RA; O'Connor T; Vassar R
J Neurosci; 2005 Nov; 25(47):10874-83. PubMed ID: 16306400
[TBL] [Abstract][Full Text] [Related]
53. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice.
McConlogue L; Buttini M; Anderson JP; Brigham EF; Chen KS; Freedman SB; Games D; Johnson-Wood K; Lee M; Zeller M; Liu W; Motter R; Sinha S
J Biol Chem; 2007 Sep; 282(36):26326-34. PubMed ID: 17616527
[TBL] [Abstract][Full Text] [Related]
54. BACE1 Cleavage Site Selection Critical for Amyloidogenesis and Alzheimer's Pathogenesis.
Zhang S; Wang Z; Cai F; Zhang M; Wu Y; Zhang J; Song W
J Neurosci; 2017 Jul; 37(29):6915-6925. PubMed ID: 28626014
[TBL] [Abstract][Full Text] [Related]
55. The beta-secretase, BACE: a prime drug target for Alzheimer's disease.
Vassar R
J Mol Neurosci; 2001 Oct; 17(2):157-70. PubMed ID: 11816789
[TBL] [Abstract][Full Text] [Related]
56. New BACE1 Chimeric Peptide Inhibitors Selectively Prevent AβPP-β Cleavage Decreasing Amyloid-β Production and Accumulation in Alzheimer's Disease Models.
Resende R; Ferreira-Marques M; Moreira P; Coimbra JRM; Baptista SJ; Isidoro C; Salvador JAR; Dinis TCP; Pereira CF; Santos AE
J Alzheimers Dis; 2020; 76(4):1317-1337. PubMed ID: 32597812
[TBL] [Abstract][Full Text] [Related]
57. BACE1: More than just a β-secretase.
Taylor HA; Przemylska L; Clavane EM; Meakin PJ
Obes Rev; 2022 Jul; 23(7):e13430. PubMed ID: 35119166
[TBL] [Abstract][Full Text] [Related]
58. Melatonin ameliorates Aβ
Chinchalongporn V; Shukla M; Govitrapong P
J Pineal Res; 2018 May; 64(4):e12470. PubMed ID: 29352484
[TBL] [Abstract][Full Text] [Related]
59. BACE1 regulates expression of Clusterin in astrocytes for enhancing clearance of β-amyloid peptides.
Zhou J; Singh N; Galske J; Hudobenko J; Hu X; Yan R
Mol Neurodegener; 2023 May; 18(1):31. PubMed ID: 37143090
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of PKCδ reduces amyloid-β levels and reverses Alzheimer disease phenotypes.
Du Y; Zhao Y; Li C; Zheng Q; Tian J; Li Z; Huang TY; Zhang W; Xu H
J Exp Med; 2018 Jun; 215(6):1665-1677. PubMed ID: 29739836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
